Danette Daniels

Excited about programming biology via induced proximity? Then mark June 2026 in your calendar and consider participating in the GRC Conference on Induced Proximity Modalities and Therapeutics that I am co-organizing with @danetteldaniels.bsky.social
tinyurl.com/brtuffam

Congratulations to the two winners of the Women in TPD & Induced Proximity conference travel scholarships @jessicagraham1.bsky.social and Leyna Duong.
We look forward to welcoming you at our #FCQC2025 in March!

@womenintpd.bsky.social @danetteldaniels.bsky.social

Thank you so much to the @womenintpd.bsky.social for this opportunity! What a fab initiative empowering women in science. Excited to connect in Frankfurt

Kudos Jessica and Leyna! Looking forward to meeting both of you in Frankfurt ☺️

Congratulations to both of you! @WomeninTPD first official scholarship award winners ☺️

Big thanks to @womenintpd.bsky.social for this amazing initiative and support in empowering women in the field! Grateful and excited to attend @keystonesymposia.bsky.social soon and make the most of this incredible experience! ✨️

Exciting advancement!

Orthogonal validation of PROTAC mediated degradation of the integral membrane proteins EGFR and c-MET - Scientific Reports Scientific Reports - Orthogonal validation of PROTAC mediated degradation of the integral membrane proteins EGFR and c-MET

If you are working on degradation of membrane proteins this work co-led by Camilla Ruffilli along with colleagues at AstraZeneca is a nice systematic look at best methods to quantitate and validate loss! www.nature.com/articles/s41...

So happy to see the growth of our initiative to now offer conference scholarships! Apply below for consideration.
Happy 2025 ☺️☀️☺️

Targeted Cancer Drugs, Succeeding and Failing

A look at why some targeted oncology drugs have succeeded in some areas and totally failed in others. The short answer: kill cancer cells - don't just slow 'em down.

Drug Discovery Approaches to Target E3 Ligases Comprehensive review presenting the different drug discovery approaches that until now have been employed in academic and pharmaceutical settings to identify new E3 ligase small molecules ligands and...

Congratulations Alejandra Rodríguez Gimeno on this review covering approaches to develop new E3 ligase binders/handles!
chemistry-europe.onlinelibrary.wiley.com/doi/full/10....

Development of a RIPK1 degrader to enhance antitumor immunity - Nature Communications It has been shown that targeting receptor-interacting protein kinase 1 (RIPK1) can improve response to immune checkpoint inhibitors. Here, using PROTAC technology, the authors report the design and ch...

New work out co-led by Xin Yu and colleagues at Baylor showing development of a selective RIPK1 degrader (VHL) and its synergy with anti-PD1 immunotherapy. Interesting potential combination to address resistance to and enhance activity of immune checkpoint inhibitors.
www.nature.com/articles/s41...

A-ha! 🧐(MassSpec humor) 🤣🤣🤣

Congrats Cris and team!

Targeted KRAS(G12V) degradation elicits efficient and durable lung adenocarcinoma regression in vivo Recent drug discovery breakthroughs led to the approval of KRASG12C inhibitors in lung adenocarcinoma (LUAD). Unfortunately, clinical responses remain limited due to rapid resistance onset. Proteolysi...

Work out co-led by Inés García Pérez and @crismayorruiz.bsky.social showing the importance of targeting KRasG12V for treatment of lung adenocarcinoma. Degradation of KRasG12V is achieved using dTAG knock-in, allowing them to building relevant mouse models.
www.biorxiv.org/content/10.1...

Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia Understanding the molecular pathogenesis of MLL fusion oncoprotein (MLL-FP) leukaemia has spawned epigenetic therapies that have improved clinical outcomes in this often-incurable disease. Using genet...

Thrilled to share a wonderful collaboration with Scott Armstrong, Florian Perner & Shellaina Gordon - exciting times ahead!

www.biorxiv.org/content/10.1...

Congratulations!

Synthetic GPCRs for programmable sensing and control of cell behaviour - Nature Modular synthetic G-protein-coupled receptors with nanobody-based ligand-recognition domains can be designed and used to programme transgene expression, real-time fluorescence or endogenous G-protein ...

Amazing new work from the lab of @aliceyting.bsky.social @stanfordmedicine.bsky.social @stanfordbiosci.bsky.social, engineered GPCRs for ligand-activated cell responses

www.nature.com/articles/s41...

Incredible meeting #CSChemBio2024 in San Francisco including talks from @fleurmferguson.bsky.social, @danetteldaniels.bsky.social, Michelle Arkin, Ingrid Wertz, and @mishtudey.bsky.social!

Fantastic also to promote this group!

Beautiful!!! Another E3 ligase that brings substrates into the center ring - incredible insight on the mechanism.

Do They Even Bind?

That awkward moment when someone publishes a paper saying that they can’t find any evidence that your compounds bind to what your own series of papers say that they bind to. . .

Critical assessment of LC3/GABARAP ligands used for degrader development and ligandability of LC3/GABARAP binding pockets - Nature Communications Autophagosome tethering compounds (ATTECs) are small molecule degraders hijacking the autophagy system. Here, the authors show that current ATTEC ligands did not bind to their designated targets but e...

Critical assessment of LC3/GABARAP ligands used for degrader development and ligandability of LC3/GABARAP binding pockets

Refreshing to see papers that go to great pains to set the record straight being published in a high profile setting

Dynamic regulation of the oxidative stress response by the E3 ligase TRIP12 The oxidative stress response is centered on the transcription factor NRF2 and protects cells from reactive oxygen species (ROS). While ROS inhibit the E3 ligase CUL3-KEAP1 to stabilize NRF2 and elici...

Excited to report our discovery of an important component of the oxidative stress response: the E3 ligase TRIP12. It acts as a chain elongation factor that amplifies CUL3-KEAP1 activity to drive NRF2 degradation as cells recover from stress.

www.biorxiv.org/content/10.1...

Congratulations! Exciting story indeed

And just like that everything is back to how it used to be! 🤣🤣🤣

Critical assessment of LC3/GABARAP ligands used for degrader development and ligandability of LC3/GABARAP binding pockets - Nature Communications Autophagosome tethering compounds (ATTECs) are small molecule degraders hijacking the autophagy system. Here, the authors show that current ATTEC ligands did not bind to their designated targets but e...

There are no shortcuts in drug discovery. And it takes incredible efforts to make sense of what you can find in the scientific literature. This is an excellent piece of work to quality check what has been claimed as a new avenue in targeted protein degradation (TPD). www.nature.com/articles/s41...

We've now filled one #Epigenetics, Chromatin and Gene regulation starter pack. Thanks for all the enthusiasm and support, if you'd like to be listed @raduzabet.bsky.social has been hard at work getting part II up and running:
go.bsky.app/SqLa3aw

My first Bluesky 🦋 post! So exciting to receive today the Epigenetic Drug Discovery book which includes our chapter on targeting chromatin remodeling complexes! #chemsky #chembio #tpd #foghorntx #oncology

📯📯NEW Chemical Biology Feed bsky.app/profile/did:...

📯List: >200 chemical biologists (probes, OC, PC, imaging): bsky.app/profile/did:...

📯Women in ChemBio Pack: bsky.app/starter-pack...

📯General #ChemBio Pack: bsky.app/starter-pack...

📯 #Photopharma: bsky.app/profile/trac...

#chemsky 🧪 🔬